JAMA Oncology SJR and Scopus Metrics: What They Actually Mean
JAMA Oncology still has elite clinical-oncology metrics, but the real submission question is whether your paper fits the journal's method-heavy editorial style.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
JAMA Oncology at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- IF 20.1 puts JAMA Oncology in a visible tier — citations from papers here carry real weight.
- Scope specificity matters more than impact factor for most manuscript decisions.
- Acceptance rate of ~~8% means fit determines most outcomes.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
- If timeline matters: JAMA Oncology takes ~21 days median. A faster-turnaround journal may suit a grant or job deadline better.
- If open access is required by your funder, verify the journal's OA agreements before submitting.
Quick answer: JAMA Oncology still has elite Scopus authority in clinical oncology. Current Scopus-based sources place it at SJR 8.377, impact score 8.32, global rank 117, and h-index 193 in 2024. That confirms genuine top-tier influence. The hard submission question is not whether the journal is strong. It is whether the manuscript is rigorous, clinically relevant, and interpretable enough for the journal's very method-heavy editorial style.
Direct answer
If your question is whether JAMA Oncology still behaves like an elite oncology journal in the Scopus system, the answer is yes.
Metric | Current value | What it tells you |
|---|---|---|
SJR | 8.377 | prestige-weighted influence remains elite in oncology |
Impact Score | 8.32 | citation density is still strong and durable |
Global rank | 117 | the journal sits near the top of the full global ranking |
h-index | 193 | the archive already has significant depth despite the journal's younger age |
Best quartile | Q1 | the title remains firmly top-tier |
Coverage history | 2015-2025 | this is a young journal with a very fast rise into the elite band |
That profile matters because JAMA Oncology is strong for a specific kind of oncology paper: clinically consequential work that is also methodologically hard to dismiss.
Overview
The useful summary is that JAMA Oncology remains in the elite clinical-oncology lane, and the 2024 numbers are slightly stronger than the 2023 profile. The SJR is up from 7.843, the impact score is up from 7.62, and the global rank improved from 126 to 117. That confirms the journal is still consolidating strength rather than flattening out.
What changed in 2024
The 2024 picture is modestly stronger across the main metrics.
- SJR moved up from 7.843 in 2023 to 8.377 in 2024
- impact score moved up from 7.62 to 8.32
- global rank improved from 126 to 117
That matters because it confirms the journal's authority is still rising at the margin. For authors, that means the editorial bar is not getting softer.
Ten-year SJR and Scopus trend
Year | SJR | Impact Score | Global Rank |
|---|---|---|---|
2024 | 8.377 | 8.32 | 117 |
2023 | 7.843 | 7.62 | 126 |
2022 | 8.103 | 8.64 | 115 |
2021 | 7.502 | 9.45 | 124 |
2020 | 8.846 | 8.60 | 101 |
2019 | 7.593 | 8.20 | 129 |
2018 | 7.604 | 7.35 | 131 |
2017 | 6.187 | 6.00 | 208 |
2016 | 4.533 | 5.04 | 338 |
2015 | 0.00 | 32774 |
The trend shows a journal that moved into the elite clinical-oncology band very quickly and has stayed there. The current numbers confirm that this is not a temporary brand halo effect.
What the trend means in practice
For authors, the trend usually means:
- the journal is strong enough to be selective on methods, not just topic importance
- broad oncology relevance matters, but clean design and interpretation matter just as much
- clinically interesting papers still fail here if the methods feel vulnerable
- a narrower oncology journal may be the honest fit for a paper with limited general clinical consequence
That is why JAMA Oncology often rejects papers that look exciting but still feel analytically loose.
How JAMA Oncology compares with realistic neighbors
Journal | Relative 2024 profile | What the metric profile usually signals |
|---|---|---|
JAMA Oncology | SJR 8.377 | elite clinical-oncology venue with strong methodological expectations |
Journal of Clinical Oncology | higher prestige weighting | broader clinical-oncology flagship with even more field-central reach |
Lancet Oncology | similar elite audience logic | stronger global-policy and practice-change framing lane |
specialty oncology journals | materially lower prestige concentration | better fit when the audience is narrower or disease specific |
This is the useful comparison. JAMA Oncology is not just another high-end oncology title. It is one of the journals where methodological discipline is part of the brand.
What editors are really screening for
The official author and journal pages make the posture clear:
- influential original research
- work that advances oncology science and clinical care
- prompt editorial decisions
- highly selective review with an 8% acceptance rate
- median time to first decision of 3 days without external review and 33 days with review
Those signals matter because they explain the metrics in operational terms. The journal can hold elite standing because it rejects quickly and selectively.
In Our Pre-Submission Review Work on JAMA Oncology Metric Questions
In our pre-submission review work on JAMA Oncology metric questions, three mistakes recur.
The method-light mistake. Authors often target the journal with clinically interesting studies whose statistical or interpretive discipline is not yet strong enough.
The narrow-oncology mistake. Another common miss is a good disease-specific paper framed as broader than it really is.
The prestige-substitution mistake. We also see teams use the JAMA label as a substitute for asking whether the paper will survive aggressive clinical and methodological scrutiny. The SJR confirms authority. It does not rescue weak design.
That is the practical value of the metrics. They explain why the journal can be both influential and highly selective.
What these metrics mean for authors
For authors, the current profile says:
- publication here still carries major signal across clinical oncology
- the journal is strong enough that analytical weaknesses become highly visible
- broad consequence and methodological cleanliness need to coexist
- if the manuscript truly fits, the visibility upside is substantial
The h-index of 193 matters because it reflects a relatively young journal that still built a deep and highly cited archive very quickly.
Submit If / Think Twice If
Submit if:
- the manuscript is methodologically clean on first read
- the clinical consequence is easy to explain to a broad oncology audience
- the study design and interpretation hold up under skeptical review
- the paper would still matter outside one disease niche
Think twice if:
- the analysis still feels vulnerable
- the audience is mainly one disease-specific or technical lane
- the clinical consequence is interesting but not clearly practice facing
- a more specialized oncology journal is the honest fit
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
What should drive the decision after the metrics check
The better question is whether the manuscript is truly a JAMA Oncology paper in its current form.
That is why the next useful reads are:
- JAMA Oncology impact factor
- JAMA Oncology submission guide
- JAMA Oncology submission process
- JAMA Oncology journal profile
If the paper is clinically consequential and methodologically sharp, the upside is real. If the methods or scope still feel soft, the metrics are mostly a warning against over-targeting. A JAMA Oncology submission framing check is the fastest way to pressure-test that before submission.
Practical verdict
JAMA Oncology still has a genuine elite Scopus profile for clinical oncology, and the 2024 numbers confirm that the journal remains solidly in that band.
For authors, the metric question is already settled. The live question is whether the manuscript is strong enough to survive the journal's characteristic mix of fast triage and demanding methodological review.
- JAMA Oncology impact factor, Manusights.
Frequently asked questions
JAMA Oncology's 2024 SJR is 8.377 on current Scopus-based metric aggregators, which keeps it in the elite tier of oncology journals.
Current Scopus-based sources place JAMA Oncology's 2024 impact score at 8.32, with a global rank of 117 and h-index of 193.
Because it remains one of the central clinical-oncology journals for high-rigor trials, observational studies, epidemiology, and policy-relevant cancer research.
No. The real question is whether the manuscript is clinically consequential and methodologically clean enough for JAMA Oncology's editorial bar.
Sources
- 1. JAMA Oncology metrics page, Resurchify.
- 2. For Authors | JAMA Oncology, JAMA Network.
- 3. Instructions for Authors | JAMA Oncology, JAMA Network.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- JAMA Oncology submission guide
- How to Avoid Desk Rejection at JAMA Oncology
- Is JAMA Oncology a Good Journal? Fit Verdict
- JAMA Oncology Impact Factor 2026: 20.1, Q1, Rank 14/326
- JAMA Oncology Acceptance Rate: What Authors Can Use
- JAMA Oncology APC and Open Access: Current AMA Pricing and When the Fee Is Worth It
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.